{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:48:53Z","timestamp":1788371333630,"version":"build-2803163510"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"UCSF Bakar Computational Health Sciences Institute and the National Center for Advancing Translational Sciences, National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR001872"],"award-info":[{"award-number":["UL1 TR001872"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000098","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 CA280811"],"award-info":[{"award-number":["U54 CA280811"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"Food and Drug Administration","doi-asserted-by":"publisher","award":["U01 FD005978"],"award-info":[{"award-number":["U01 FD005978"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Importance: Multiple myeloma (MM) is the second most common hematologic malignancy in the U.S., with a higher incidence among Black patients than White patients. Chimeric antigen receptor T-cell (CAR-T) therapies show clinical promise, but their limited availability raises concerns about access. Objective: To examine associations between disease characteristics, treatment location, and patient demographics with receipt of CAR-T therapy among patients with MM. Design: Retrospective cohort study using electronic health record data from the University of California Health Data Warehouse (UCHDW) between January 2021 and January 2025. Setting: Six academic health centers and twelve affiliated hospitals within the UCHDW. Participants: A population-based cohort of 12,360 adult patients diagnosed with MM and treated at a University of California facility offering CAR-T administration. Analyses were conducted from February 2025 to March 2025. Exposures: Receipt of multiple cancer therapies following MM diagnosis. Main Outcomes and Measures: Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between disease characteristics, treatment locations, and patient demographics with receipt of CAR-T therapy. A zero-shot GPT-4 inference model was applied to UCSF clinical notes to assess whether CAR-T therapy was discussed, determine documented eligibility, and classify rationale for eligibility determinations. Results: Among 12,360 patients with MM (mean age, 68.5 years; 51.6% male), 320 (2.6%) received CAR-T therapy. Disease characteristics at diagnosis, measured by the International Staging System (ISS), was distributed as follows: Stage I (65.3%), Stage II (24.4%), Stage III (2.8%), and Unknown (7.5%). Patients treated at UC-1 (49.3%), and UC-2 (50.0%) were more frequently diagnosed with ISS Stage II, whereas patients treated at UC-3 (55.5%) were more frequently diagnosed with ISS Stage I. Our model showed that patients identifying as Black or African American had lower odds of receiving CAR-T therapy compared with White patients (OR, 0.33; [95% CI, 0.17\u20130.62]). Patients treated at UC-3 also had lower odds of receiving CAR-T therapy compared with UC-1 (OR, 0.42; [95% CI, 0.30\u20130.59]). Among 270 UCSF patients assessed for CAR-T eligibility using clinical notes, the proportion of patients deemed eligible without documented CAR-T discussions was highest among those identifying as Other Pacific Islander (50%), followed by Black or African American (4.2%), Asian (3.2%), and White patients (0.6%). Conclusions and Relevance: Within a large academic health system, receipt of CAR-T therapy varied by treatment location and patient-reported race. A subset of patients with documented eligibility lacked recorded discussions of CAR-T therapy, suggesting potential differences in referral, documentation, or care pathways influencing observed treatment patterns.<\/jats:p>","DOI":"10.3390\/cancers18040669","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:59:16Z","timestamp":1771419556000},"page":"669","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-9872","authenticated-orcid":false,"given":"Jays\u00f3n","family":"Davidson","sequence":"first","affiliation":[{"name":"Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA 94158, USA"},{"name":"Center for Data-Driven Insights and Innovation, University of California Health, Oakland, CA 94607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayan","family":"Patel","sequence":"additional","affiliation":[{"name":"Center for Data-Driven Insights and Innovation, University of California Health, Oakland, CA 94607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Computational Precision Health, University of California San Francisco, San Francisco, CA 94158, USA"},{"name":"University of California Berkeley, Berkeley, CA 94117, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-2740","authenticated-orcid":false,"given":"Atul J.","family":"Butte","sequence":"additional","affiliation":[{"name":"Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA 94158, USA"},{"name":"Center for Data-Driven Insights and Innovation, University of California Health, Oakland, CA 94607, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Zack","sequence":"additional","affiliation":[{"name":"Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA 94158, USA"},{"name":"Center for Data-Driven Insights and Innovation, University of California Health, Oakland, CA 94607, USA"},{"name":"Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA 94143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"ref_1","unstructured":"(2022, April 03). American Cancer Society Cancer Statistics Center. 2022 Estimates. Available online: https:\/\/cancerstatisticscenter.cancer.org\/#!\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.33696\/haematology.4.055","article-title":"Analysis of Updates in Multiple Myeloma Treatment and Management","volume":"4","author":"Nieto","year":"2023","journal-title":"J. Clin. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-020-00347-6","article-title":"Racial differences in treatment and outcomes in multiple myeloma: A multiple myeloma research foundation analysis","volume":"10","author":"Derman","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.amjmed.2022.08.030","article-title":"Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations","volume":"136","author":"Mikhael","year":"2023","journal-title":"Am. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-023-00877-9","article-title":"Global disparities in patients with multiple myeloma: A rapid evidence assessment","volume":"13","author":"Mateos","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: A matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: A SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: A SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med."},{"key":"ref_9","first-page":"29","article-title":"Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review","volume":"5","author":"Alam","year":"2023","journal-title":"Clin. Hematol. Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1189.e1","DOI":"10.1016\/j.jtct.2024.09.010","article-title":"Racial and Ethnic Disparities in Autologous Hematopoietic Cell Transplantation Utilization in Multiple Myeloma Have Persisted Over Time Even After Referral to a Transplant Center","volume":"30","author":"Wu","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.HS9.0000936164.84357.ed","article-title":"P09 daratumumab plus lenalidomide and dexamethasone (d-rd) versus lenalidomide and dexamethasone (rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (ndmm): Updated analysis of the phase 3 maia study","volume":"7","author":"Weisel","year":"2023","journal-title":"HemaSphere"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: Unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Jogalekar, M.P., Rajendran, R.L., Khan, F., Dmello, C., Gangadaran, P., and Ahn, B.C. (2022). CAR T-Cell-Based gene therapy for cancers: New perspectives, challenges, and clinical developments. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.925985"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1038\/s41467-019-11069-0","article-title":"Integrating biomedical research and electronic health records to create knowledge-basedbiologically meaningful machine-readable embeddings","volume":"10","author":"Nelson","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Biedermann, P., Ong, R., Davydov, A., Orlova, A., Solovyev, P., Sun, H., Wetherill, G., Brand, M., and Didden, E.-M. (2021). Standardizing registry data to the OMOP Common Data Model: Experience from three pulmonary hypertension databases. BMC Med. Res. Methodol., 21.","DOI":"10.1186\/s12874-021-01434-3"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Vandenbroucke, J.P., von Elm, E., Altman, D.G., G\u00f8tzsche, P.C., Mulrow, C.D., Pocock, S.J., Poole, C., Schlesselman, J.J., Egger, M. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040297"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.2105\/AJPH.93.7.1137","article-title":"Area deprivation and widening inequalities in US mortality, 1969\u20131998","volume":"93","author":"Singh","year":"2003","journal-title":"Am. J. Public Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"pkaa011","DOI":"10.1093\/jncics\/pkaa011","article-title":"Area Deprivation Index and Rurality in Relation to Lung Cancer Prevalence and Mortality in a Rural State","volume":"4","author":"Fairfield","year":"2020","journal-title":"JNCI Cancer Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11605-020-04754-9","article-title":"Association of Socioeconomic Area Deprivation Index with Hospital Readmissions After Colon and Rectal Surgery","volume":"25","author":"Ghirimoldi","year":"2021","journal-title":"J. Gastrointest. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2250416","DOI":"10.1001\/jamanetworkopen.2022.50416","article-title":"Evaluation of Social Determinants of Health and Prostate Cancer Outcomes Among Black and White Patients: A Systematic Review and Meta-analysis","volume":"6","author":"Vince","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1062860617753063","article-title":"Area Deprivation Index Predicts Readmission Risk at an Urban Teaching Hospital","volume":"33","author":"Hu","year":"2018","journal-title":"Am. J. Med. Qual."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2238183","DOI":"10.1001\/jamanetworkopen.2022.38183","article-title":"Association of Race and Area Deprivation With Breast Cancer Survival Among Black and White Women in the State of Georgia","volume":"5","author":"Luningham","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.13063\/2327-9214.1238","article-title":"Introduction of an Area Deprivation Index Measuring Patient Socioeconomic Status in an Integrated Health System: Implications for Population Health","volume":"4","author":"Knighton","year":"2016","journal-title":"EGEMS"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMp1802313","article-title":"Making Neighborhood-Disadvantage Metrics Accessible\u2014The Neighborhood Atlas","volume":"378","author":"Kind","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Fischer, M., and Getis, A. (2010). Spatial Statistics in ArcGIS. Handbook of Applied Spatial Analysis, Springer.","DOI":"10.1007\/978-3-642-03647-7"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Agresti, A. (2002). Categorical Data Analysis, John Wiley & Sons, Inc.. [2nd ed.].","DOI":"10.1002\/0471249688"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Harrell, F.E. (2001). Regression Modeling Strategies, Springer.","DOI":"10.1007\/978-1-4757-3462-1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jtct.2023.03.012","article-title":"Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.jgo.2023.101628","article-title":"Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis","volume":"15","author":"Akhtar","year":"2024","journal-title":"J. Geriatr. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e6905","DOI":"10.1002\/cam4.6905","article-title":"Effects of socioeconomic status on enrollment in clinical trials for cancer: A systematic review","volume":"13","author":"Donzo","year":"2024","journal-title":"Cancer Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T13:00:42Z","timestamp":1771419642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/4\/669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["cancers18040669"],"URL":"https:\/\/doi.org\/10.3390\/cancers18040669","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]}}}